Latest News
From EHR Data to Real-World Evidence: Health IT Meets R&D
For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...
Latest News
Creative Biolabs’ CAR Engineering: Moving Cell Programming Inside the Body
CAR cell therapy has demonstrated that immune cells can be genetically programmed to recognize and attack disease-associated targets. Yet conventional CAR-T therapy generally depends on an elaborate ex vivo workflow involving cell collection, genetic modification,...
Genglycos Gene Therapy Approval Sets New Bar for Rare Metabolic Disease
The Genglycos gene therapy approval gives patients with glycogen storage disease type Ia a new option. The FDA describes it as the first approved treatment for the condition. It is designed to address the underlying cause. The US Food and Drug Administration granted...
AI-Discovered Drugs in 2026: The State of Play
Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...
Why Ingredient Research Is Only the Beginning of a Health Product
I spent years formulating low-carbohydrate, low-calorie, high-protein and gluten-free foods. That work taught me a lesson that is easy to miss when a new ingredient has exciting research behind it: an ingredient is not a finished product. A study can tell you that an...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Panthera Opens New Clinical Research Clinic at Keele University
13 August 2026 - Panthera has opened its latest clinical trial clinic at Keele University, further strengthening its growing clinical research network across the UK and Europe. Panthera, which is the UK's largest independent Site Management Organisation (SMO),...
Clinical Trials Roundup | 14 Aug 2026
Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...
From Laboratory to Market: Risk Planning for Life Science Companies
The UK life sciences sector is entering an important phase of growth. The Government's Life Sciences Sector Plan sets an ambition for the UK to become the leading life sciences economy in Europe by 2030 and the third globally by 2035. It also reports that the sector...
Biopharma VC Funding in H1 2026: Megarounds Mask an Early-Stage Squeeze
Biopharma VC funding delivered its strongest opening half in four years. Yet the headline figure hides a widening split. Mature, de-risked companies are attracting capital, while the seed-stage startups that supply the sector’s long-term pipeline are not. Data...
Organ Digital Twins: Inside Imperial College London’s Research
Organ digital twins have moved from mathematical curiosity to funded national priority. Imperial College London now sits close to the centre of that shift. Researchers there have built more than 3,800 anatomically accurate virtual hearts. They have also begun an NHS...
Glass Slides to AI: Digital Pathology Can Transform Cancer Care in the NHS
Every year, millions of pathology slides are produced in the UK, most still examined manually under a microscope. This century-old process, though reliable, is no longer fit for purpose. Pathology departments face mounting workforce pressures, with 78% pathologists...
Kidney Care’s $2.5 Billion Timing Problem
Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...
Blood Supplies Set For Vital Boost as Donation Rules Are Updated
Long-running campaign removes unnecessary barrier for blood donors, a victory for both patients and the blood donation service* Patients receiving acupuncture from appropriately qualified practitioners will no longer have to wait four months before donating blood,...
In Vivo CAR-T Therapy: The Next Frontier in Cell Therapy Explained
In vivo CAR-T therapy has travelled from laboratory concept to clinical reality faster than almost any modality in recent memory. Conventional cell therapy collects a patient’s T cells, engineers them in a specialist facility and returns them weeks later. The in vivo...
Cutting Through the Noise: How AI/ML Can Guide Target Selection for Vaccines
Modern vaccine research has entered an era of colossal data abundance. Researchers can now examine complete pathogen genomes and proteomes, measure hundreds of thousands of antigen-specific antibody responses, characterize immune-cell states at single-cell resolution...
Beyond Weight Loss: What Emerging GLP-1 Research Reveals
For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...
GLP-1 Side Effects: What the Evidence Actually Says
An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...
Panthera Opens New Clinical Research Clinic at Keele University
13 August 2026 - Panthera has opened its latest clinical trial clinic at Keele University, further strengthening its growing clinical research network across the UK and Europe. Panthera, which is the UK's largest independent Site Management Organisation (SMO),...
Clinical Trials Roundup | 14 Aug 2026
Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...
From Laboratory to Market: Risk Planning for Life Science Companies
The UK life sciences sector is entering an important phase of growth. The Government's Life Sciences Sector Plan sets an ambition for the UK to become the leading life sciences economy in Europe by 2030 and the third globally by 2035. It also reports that the sector...
Biopharma VC Funding in H1 2026: Megarounds Mask an Early-Stage Squeeze
Biopharma VC funding delivered its strongest opening half in four years. Yet the headline figure hides a widening split. Mature, de-risked companies are attracting capital, while the seed-stage startups that supply the sector’s long-term pipeline are not. Data...
Organ Digital Twins: Inside Imperial College London’s Research
Organ digital twins have moved from mathematical curiosity to funded national priority. Imperial College London now sits close to the centre of that shift. Researchers there have built more than 3,800 anatomically accurate virtual hearts. They have also begun an NHS...
Glass Slides to AI: Digital Pathology Can Transform Cancer Care in the NHS
Every year, millions of pathology slides are produced in the UK, most still examined manually under a microscope. This century-old process, though reliable, is no longer fit for purpose. Pathology departments face mounting workforce pressures, with 78% pathologists...
Kidney Care’s $2.5 Billion Timing Problem
Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...
Blood Supplies Set For Vital Boost as Donation Rules Are Updated
Long-running campaign removes unnecessary barrier for blood donors, a victory for both patients and the blood donation service* Patients receiving acupuncture from appropriately qualified practitioners will no longer have to wait four months before donating blood,...
In Vivo CAR-T Therapy: The Next Frontier in Cell Therapy Explained
In vivo CAR-T therapy has travelled from laboratory concept to clinical reality faster than almost any modality in recent memory. Conventional cell therapy collects a patient’s T cells, engineers them in a specialist facility and returns them weeks later. The in vivo...
Cutting Through the Noise: How AI/ML Can Guide Target Selection for Vaccines
Modern vaccine research has entered an era of colossal data abundance. Researchers can now examine complete pathogen genomes and proteomes, measure hundreds of thousands of antigen-specific antibody responses, characterize immune-cell states at single-cell resolution...
Beyond Weight Loss: What Emerging GLP-1 Research Reveals
For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...
GLP-1 Side Effects: What the Evidence Actually Says
An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...
Featured Articles
Further News
Bridging Cosmetic Science & Clinical Research: When Beauty Becomes Therapeutic
The evolving landscape of cosmetic science is increasingly defined by its convergence with clinical research, challenging long-standing distinctions between aesthetic enhancement and therapeutic intervention. Historically, cosmetics have been confined to products...
Asia Is No Longer Pharma’s Factory. It Is Becoming the Source
Two deals announced within days of each other this month read, on their own, like routine deal flow news. South Korea’s Alteogen signed its seventh platform licensing agreement with a global pharmaceutical company. Fujifilm and Taiho Pharmaceutical agreed to build...
Catching Pediatric Strabismus: When It Is More Than a Glare Reaction
Monocular eye closure in bright sunlight glare can often be interpreted as a benign photic response in pediatric patients. However, the behavior may point to an early or intermittent manifestation of binocular vision dysfunction such as intermittent exotropia....
Regulation Is Pushing European Medtechs to Streamline Clinical Trials
Europe’s changing macroeconomic and regulatory environment is prompting the medtech industry to rethink clinical processes and technologies. New insights reveal focus on establishing a unified digital foundation as medtech companies look to optimise data strategy,...
Treating Antimicrobial Resistance as a Healthcare Infrastructure Priority
Modern healthcare depends on a basic assumption: when infections occur, clinicians will have medicines that can treat them. But antimicrobial resistance (AMR) is beginning to challenge that assumption at a systems level. For many years, AMR has been discussed...
Weekly News Roundup | 10 August 2026
Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...
Beyond Cytotoxic Payloads: The Expansion of Non-traditional Conjugates
For over two decades, the narrative surrounding targeted biologics has been dominated by antibody-drug conjugates (ADCs) armed with cytotoxic small molecules designed to destroy cancer cells. While oncology remains a primary target for biologics, the therapeutic...
The Public Paper Trail: What Commercial Teams Find Out Last
For most of a decade, I worked on the commercial side of life sciences, and the same thing kept happening. Something would change at an account. A financing would close, a trial would move into a new phase, or a facility would receive an inspection observation. I...
Clinical Trials Roundup | 07 Aug 2026
Merck’s tulisokibart meets its primary and key secondary endpoints in a Phase 2 hidradenitis suppurativa study but misses in systemic sclerosis-associated interstitial lung disease, Eli Lilly’s olomorasib receives a second FDA Breakthrough Therapy designation in KRAS...
Why AI Pilots Fail in Life Sciences
Misaligned incentives, the wrong unit of work, and a probabilistic model where the process demands a reproducible one A draft annex to European GMP guidance, out for consultation until October 2025, contains the bluntest sentence yet written about AI in regulated...
Prevention by Design: How Korea’s Health System Diverges from America’s
South Korea and the United States are both wealthy, technologically sophisticated countries with excellent physicians and world-class hospitals. Yet they placed opposite structural bets on what a health system is for. America bet on treating disease as well as it can...
New Approach Methodologies: What Regulators Now Accept
New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.